Finance

Lists
Why is ALNEV down 10.44%?
Dive Deeper
ALNEV:EPA
Neovacs SA
€0.069
-10.44%
(-0.0080) 1D
Nov 13, 5:35:25 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALNEV...
Open
€0.08
High
€0.08
Low
€0.07
Mkt. cap
2.12K
Avg. vol.
175.85K
Volume
307.34K
52-wk high
€318.00
52-wk low
€0.06
EPS
-€667.70
Shares outstanding
1.82M
No. of employees
11
Open
€0.08
High
€0.08
Low
€0.07
Mkt. cap
2.12K
Avg. vol.
175.85K
Volume
307.34K
52-wk high
€318.00
52-wk low
€0.06
EPS
-€667.70
Shares outstanding
1.82M
No. of employees
11
News stories
From web sources and news partners
About Neovacs SA
CEO-
Employees11
Founded1993
Headquarters-
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
284.60K
284.60K
Cost of goods sold
-
-
731.45K
731.45K
Cost of revenue
-
-
731.45K
731.45K
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-
-
545.20K
545.20K
Operating expense
-
-
609.85K
609.85K
Total operating expenses
-
-
1.34M
1.34M
Operating income
-
-
-1.06M
-1.06M
Other non operating income
-
-
85.21K
85.21K
EBT including unusual items
-
-
-971.49K
-971.49K
EBT excluding unusual items
-
-
-971.49K
-971.49K
Income tax expense
-
-
-157.18K
-157.18K
Effective tax rate
-
-
16.18%
16.18%
Other operating expenses
-
-
27.27K
27.27K
Net income
-
-
-814.31K
-814.31K
Net profit margin
-
-3,154.93%
-286.13%
-286.13%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
37.37K
37.37K
EBITDA
-
-
-801.63K
-801.63K
Gain or loss from assets sale
-
-
100.00
100.00
Upcoming events
AI content may include mistakes. Learn more
Google apps